Stjórn Reita fasteignafélags hf. samþykkti nýja endurkaupaáætlun félagsins þann 1. júlí 2025 sbr. tilkynningu í Kauphöll þann dag. Var henni hrint í framkvæmd þann 2. júlí 2025. Endurkaupaáætlunin er framkvæmd í samræmi við ákvæði hlutafélagalaga nr. 2/1995, 5. gr. reglugerðar Evrópuþingsins og ráðsins (ESB) um markaðssvik nr. 596/2014, sem og framselda reglugerð framkvæmdastjórnarinnar 2016/1052, samanber lög um aðgerðir gegn markaðssvikum nr. 60/2021.
Cult mobile phenomenon arrives soon as a fully enhanced 1.0 PC edition, co-published by Playsaurus and Ultraplayers. Art direction by internet-famous surrealist MasterTingus.
SYDNEY and...
July retail sales at Kia dealerships increased 9 percent year-over-year, achieving best-ever July resultYear-to-date Kia sales are up 8 percent over 2024's all-time record...
DALLAS, July 30, 2025 /PRNewswire/ -- Brinker International, Inc. (NYSE: EAT) has scheduled its earnings conference call at 10 a.m. Eastern Time on Wednesday,...
TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.